Lilly’s investigational drug met primary and key secondary endpoints in ATTAIN-2, showing significant weight loss and reduced A1c in people with obesity or overweight and type 2 diabetes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/orforglipron-phase-3-success-prompts-submissions-obesity-2025a1000mkb?src=rss
Author :
Publish date : 2025-08-26 19:34:00
Copyright for syndicated content belongs to the linked Source.
